Addison's disease, also known as primary adrenal insufficiency, is a rare disorder where the adrenal glands do not produce enough cortisol and, sometimes, aldosterone. Companies involved in addressing Addison's disease typically focus on developing medications, hormone replacement therapies, and other medical interventions to manage the symptoms and improve the quality of life for individuals with this condition.
Novartis initiated a Phase 3 study in July 2023 investigating the efficacy and safety of pasireotide LAR for Addison's disease. This potential long-acting somatostatin analog therapy could offer improved convenience and compliance for patients.
Corcept Therapeutics is conducting a Phase 2b study assessing mifepristone for the treatment of autoimmune adrenal insufficiency (Addison's disease). This potential steroidogenic inhibitor could offer a novel treatment option with potentially fewer side effects.
In November 2023, Spruce Biosciences presented positive results from their Phase 2 clinical trial evaluating tildacerfont, an investigational therapy for congenital adrenal hyperplasia (CAH), which often co-occurs with Addison's disease. These results could pave the way for further development of tildacerfont for patients with both conditions.
List of Addison’s Disease Key Companies in the Market
Addison’s Disease Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)